Boston University & Med-IQ: The Treatment Decision-Making Process: When to Consider or Defer BCMA-Directed BsAbs in a Patient’s MM Treatment Journey
This CME activity explores the latest clinical data and provides guidance on when to consider treatment with available B-cell maturation antigen (BCMA)-directed bispecific antibodies (BsAbs), chimeric antigen receptor (CAR) T-cell therapy, or antibody-drug conjugate (ADC) therapy for patients with relapsed/refractory multiple myeloma (RRMM) based on patient-, disease-, and treatment-related factors.
Cost: Free
View Offer chevron_rightKey Features
Reviews the latest evidence and treatment selection considerations for BCMA-directed bispecific antibodies, CAR T-cell therapy, and ADCs in relapsed/refractory multiple myeloma.
Topics Covered
BCMA-directed bispecific antibodies for the treatment of multiple myeloma
Learning Objectives
Upon completion, participants should be able to:
- Appropriately incorporate BCMA-directed BsAbs into cases of patients with MM that are representative of clinical practice
Target Audience
This program is intended for oncologists, hematologists, physician associates, nurse practitioners, nurses, nurse navigators, pharmacists, and other healthcare professionals responsible for the care and treatment of people living with RRMM.
Additional credit info
Boston University Chobanian & Avedisian School of Medicine designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine Maintenance of Certification (MOC) Part 2 Credit. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By participating and claiming credit, you agree to BU sharing your information with ACCME PARS the data conduit to the ABIM.
This activity is approved for 0.5 CPE credit. UAN is: JA0000185-9999-26-040-H01-P.
Nursing Contact Hours: 0.5, of which none are eligible for pharmacology credit.
Boston University Chobanian & Avedisian School of Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.